Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated July 18, 2024, serves as a transaction notification for the month of July 2024. The document details share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) resulting from dividend reinvestment plans.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific equity transactions.
| Transaction Date | Instrument | Price | Total Volume (Shares/ADS) | Exchange |
|---|---|---|---|---|
| 2024-07-16 | Ordinary Shares | £14.9318 | 20,600.473 | London Stock Exchange (XLON) |
| 2024-07-16 | American Depositary Shares (ADS) | $38.7368 | 3,319.997 | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely records routine share acquisitions by executives and directors following the dividend payment date of July 11, 2024.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs and PCAs against the company's latest insider trading reports.
- Confirm the dividend reinvestment price (£14.9318 for Ordinary Shares and $38.7368 for ADSs) against market data for July 16, 2024.
- Review the list of participating executives to ensure all required disclosures for the period are complete.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.